RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) granted stock options and restricted stock units covering a combined 26,040 shares to a newly hired non-executive employee on Nov. 3, 2026, using equity compensation to support recruitment as the Radnor-based biotechnology company develops treatments for hypertension and related conditions.
The company’s board compensation committee approved an option award covering 14,880 shares and a restricted stock unit award covering 11,160 shares of Mineralys common stock.
Both awards were issued under the company’s 2025 Employment Inducement Incentive Award Plan, which provides equity incentives to new employees.
The grants were made under Nasdaq Listing Rule 5635(c)(4), which permits qualifying employment inducement awards without shareholder approval when the awards are material to an individual’s decision to join a company.
The stock options and restricted stock units are subject to four-year vesting schedules, tying the employee’s ability to receive the full benefits of the awards to continued employment.
For the stock option award, 25% of the underlying shares will vest on Nov. 2, 2027, the first anniversary of the vesting commencement date.
The remaining options will vest in monthly installments equal to one-48th of the total award following each additional month of service, completing the four-year schedule.
The restricted stock units will vest in four equal annual installments, with 25% becoming vested on each anniversary of the Nov. 2, 2026, commencement date.
Continued service with Mineralys is required for vesting under both awards.
The grants represent equity-based compensation rather than an immediate issuance of all 26,040 shares.
Mineralys is developing treatments targeting hypertension and medical conditions associated with dysregulated aldosterone, a hormone involved in regulating blood pressure and fluid balance.
Its lead investigational drug, lorundrostat, is an orally administered, selective aldosterone synthase inhibitor designed to reduce aldosterone production.
The company’s development focus includes hypertension and related conditions such as chronic kidney disease and obstructive sleep apnea.
Founded by Catalys Pacific, Mineralys is headquartered in Radnor, Pennsylvania.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.